Cite
HARVARD Citation
Collins, S. et al. (n.d.). 357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma. Journal for immunotherapy of cancer. p. A218. [Online].